JAMA psychiatry
February 1, 2025
Daniel T Myran, Michael Pugliese, Jennifer Xiao et al.
23 citations
People who had an emergency department visit involving hallucinogen use were more likely to be diagnosed with a schizophrenia spectrum disorder within three years compared with the general population (3.99% vs 0.15%). After accounting for other substance use and mental health conditions, the risk remained elevated: they were about 3.5 times as likely as the general population, 4.7 times as likely as those with an alcohol-related ED visit, and 1.5 times as likely as those with a cannabis-related ED visit. The rate of hallucinogen-related ED visits rose 86% between 2013 and 2021.
Eur Neuropsychopharmacol
November 7, 2025
Mikkel Højlund, Helin Y. Kafali, Begüm Kırmızı et al.
12 citations
A living systematic review with meta-analysis examined the efficacy, safety, and all-cause discontinuation of serotonergic psychedelics and MDMA for treating mental disorders. The review found that these substances show promise in reducing symptoms of conditions such as depression, anxiety, and post-traumatic stress disorder, with some evidence supporting their therapeutic potential. However, the authors note that the overall quality of evidence is limited by small sample sizes, short follow-up periods, and methodological concerns. Safety profiles varied, with most adverse events being mild to moderate, though serious adverse events were reported in some studies. The review emphasizes the need for larger, more rigorous trials to confirm these findings.
CMAJ
March 2, 2025
Daniel T. Myran, Jennifer Xiao, Nicholas Fabiano et al.
8 citations
People who had an emergency department visit or hospital admission involving hallucinogen use in Ontario, Canada, between 2006 and 2022 had a 2.6-fold higher risk of death from any cause within five years compared with the general population. Among 7953 individuals with such acute care, 6.1% died within five years versus 0.6% in the matched general population. Elevated risks were also seen for death from unintentional drug poisoning, suicide, respiratory disease, and cancer. These associations persisted even after excluding people with other mental or substance use disorders.
Translational Psychiatry
February 27, 2026
Alex Gearin, Jennifer Docherty, Xiaofan Sun et al.
1 citation
Psychedelic-assisted therapies show clinical promise for reducing depression and anxiety in patients with life-limiting illness, but most protocols reflect Euro-American values. Using Chinese palliative care as an example, the commentary argues that cultural factors such as family-centered decision-making, spiritual beliefs, and stigma will shape how these therapies work in different settings. Cultural humility—ongoing self-reflection, sensitivity to power dynamics, and openness to diverse worldviews—is essential for psychedelic therapy, where patient experiences depend on context and meaning-making. Efficacy is not solely biochemical but also cultural; addressing this translational gap requires humility toward how situated beliefs, norms, and practices interact with psychedelic pharmacology.